While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

And our discussion with Amgen, a company is bringing innovative ... it's good to have competition in a field that is new, that will be best for patients, and it helps keep industry partners ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

For tech companies, the healthcare vertical is now the fastest growing business. The US, which spends about $5 trillion on ...

Prolia made $2.3 billion in sales for Amgen last year but is a few years away from patent expiry, putting it at risk of biosimilar competition. Evenity works in a different way to Prolia ...

Founder and CEO of Zander's Game House, Jeanne Slkoff, spoke about her business during Spring Semester Entrepreneur Speaker ...

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...